We are live on ! Find out more
FBT icon

First Trust NYSE Arca Biotechnology Index Fund

112 hedge funds and large institutions have $398M invested in First Trust NYSE Arca Biotechnology Index Fund in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

26% more capital invested

Capital invested by funds: $317M → $398M (+$81.6M)

23% more call options, than puts

Call options by funds: $1.66M | Put options by funds: $1.35M

17% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 30

4.12% more ownership

Funds ownership: 34.89%39.02% (+4.1%)

0% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 22

1% less funds holding

Funds holding: 113112 (-1)

Holders
112
Holders Change
-1
Holders Change %
-0.88%
% of All Funds
2.79%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
22
Increased
35
Reduced
30
Closed
22
Calls
$1.66M
Puts
$1.35M
Net Calls
+$307K
Net Calls Change
-$1.38M

FBT Hedge Fund Activity: Q2 2017 in Review

112 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q2 2017, worth a combined $398M — up 26% from $317M a quarter earlier.

Fund positioning in FBT was balanced in Q2 2017: 22 funds opened new positions, 22 closed out, 35 added to existing stakes and 30 trimmed.

The largest buyer was Navellier & Associates, opening a new position worth an estimated $17.2M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $2.27M sold.

  • 112 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q2 2017, down from 113 in Q1 2017.
  • Funds reported $398M of First Trust NYSE Arca Biotechnology Index Fund stock for Q2 2017, up 26% quarter-over-quarter.
  • 22 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q2 2017 and 22 closed out, a net change of 0 holders.
  • The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q2 2017 was Navellier & Associates, an estimated $17.2M added.
  • The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q2 2017 was Susquehanna International Group, an estimated $2.27M sold.

Based on aggregated 13F filings for Q2 2017.